Avoid common mistakes on your manuscript.
Correction: Journal of Ultrasound (2023) 26:749–756 https://doi.org/10.1007/s40477-023-00809-0
In page 5, 2nd column, 2nd paragraph has been incorrectly published in the original publication as:
Several biomarkers have been investigated as endogenous targets for USMI, of which the most studied are some types of integrin, endoglin and, above all, VEGFR-2. The latter is the molecular target of the first compound that entered the clinical phases of drug development and approved by the FDA, known commercially as BR55® (Bracco Suisse SA, Geneva, Switzerland). It consists of a gas core (a mixture of perfluorobutane and nitrogen), surrounded by a phospholipid shell with an average diameter of 1.5 μm: the ligand is a heterodimeric peptide with target epresented by the KDR insert of VEGFR-2, covalently conjugated through its amino-terminal group with a pegylated lipopeptide construct (Fig. 5) [21]
The complete correct paragraph should be read as follows.
Several biomarkers have been investigated as endogenous targets for USMI, of which the most studied are some types of integrin, endoglin and, above all, VEGFR-2. The latter is the molecular target of the first compound that entered the clinical phases of drug development and known as BR55 (Bracco Suisse SA, Geneva, Switzerland). It consists of a gas core (a mixture of perfluorobutane and nitrogen), surrounded by a phospholipid shell with an average diameter of 1.5 μm: the ligand is a heterodimeric peptide with target represented by VEGFR-2, which is also known as KDR (kinase-insert domain- receptor), covalently conjugated through its amino-terminal group with a pegylated lipopeptide construct (Fig. 5) [21]
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Monzeglio, O., Melissa, V.M., Rodolfi, S. et al. Correction: Exploring the potential of contrast agents in breast cancer echography: current state and future directions. J Ultrasound (2024). https://doi.org/10.1007/s40477-024-00892-x
Published:
DOI: https://doi.org/10.1007/s40477-024-00892-x